South Africa's HIV Response: Hope, Tools, and Resolve
Image: Tumi Pakkies/ Independent Newspapers
Earlier this month, more than 3,600 scientists, activists, policymakers, and journalists gathered in Kigali, Rwanda, for the 13th International AIDS Society (IAS) Conference on HIV Science.
It was the first time this major global event took place in an African city outside South Africa, marking a powerful recognition of the continent's critical role in the global HIV response.
The conference came on the heels of deeply concerning news: in January, the US government announced sharp cuts to funding for the President's Emergency Plan for AIDS Relief (PEPFAR), a move that cast a long shadow over the global fight against HIV, particularly in Africa. The numbers are staggering: of the 40.8 million people living with HIV globally, over 26 million (65%) are in Africa. And more than half of all new infections in 2024 occurred on the continent.
A Call to Stay the Course
Despite fears about reduced funding, the mood in Kigali was one of resolve. Delegates affirmed their commitment to ending HIV, recognising the extraordinary progress made in Eastern and Southern Africa. Many echoed a common sentiment: "We cannot stop now. We must fight to the end", emphasising the need for sustained commitment and effort to achieve an AIDS-free future.
That optimism was reinforced by encouraging developments. The pharmaceutical company Gilead announced that Lenacapavir, a new HIV prevention drug administered via two injections a year, has shown high efficacy in clinical trials. If made widely accessible, this could be a game-changer— especially for those who struggle with daily pill regimens.
Further hope came when the US Congress ultimately approved continued PEPFAR funding, although uncertainties remain around the duration and scope of future support.
Video Player is loading.
Play Video
Play
Unmute
Current Time
0:00
/
Duration
-:-
Loaded :
0%
Stream Type LIVE
Seek to live, currently behind live
LIVE
Remaining Time
-
0:00
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
Text Color White Black Red Green Blue Yellow Magenta Cyan
Transparency Opaque Semi-Transparent Background Color Black White Red Green Blue Yellow Magenta Cyan
Transparency Opaque Semi-Transparent Transparent Window Color Black White Red Green Blue Yellow Magenta Cyan
Transparency Transparent Semi-Transparent Opaque
Font Size 50% 75% 100% 125% 150% 175% 200% 300% 400% Text Edge Style None Raised Depressed Uniform Dropshadow Font Family Proportional Sans-Serif Monospace Sans-Serif Proportional Serif Monospace Serif Casual Script Small Caps
Reset
restore all settings to the default values Done
Close Modal Dialog
End of dialog window.
Advertisement
Next
Stay
Close ✕
Ad loading
What This Means for South Africa
South Africa has the world's largest HIV treatment programme, with over 5.5 million people receiving antiretrovirals (ARVs). Yet we still see more than 100 000 new HIV infections each year. That is unacceptable — and preventable.
To address this, the government launched the '1.1 Million Campaign' in February to close the gap between those who know their HIV status and those who are virally suppressed. But for this initiative to succeed, we need national mobilisation.
Every political leader, community organiser, religious institution, and employer must actively support the campaign. Unfortunately, media coverage has been limited, and public awareness remains low.
Doing More with Less
With reductions in funding from the Global Fund and PEPFAR, and despite increased domestic investment, every rand in our HIV response must count. Managers and community activists in the health and social development sectors must track data rigorously: Who is being tested? Who is on treatment? Who is virally suppressed? Who is using Pre-Exposure Prophylaxis (PrEP) — and who should be, but isn't?
We must also stand firm against stigma. There is no justification for discrimination against people living with HIV or those using preventive treatments like PrEP. They are taking responsible steps to protect themselves and others. They should be commended and supported, not shamed.
The Tools Are in Our Hands
We now have powerful tools to fight HIV. HIV self-test kits are available free at public clinics and affordable at private pharmacies. Oral PrEP— a once-a-day pill to prevent HIV — is also free at government health facilities. And injectable PrEP, which could significantly improve adherence, is expected to be available next year.
Condoms remain a highly effective prevention method. Let's not forget—they also prevent sexually transmitted infections like syphilis and gonorrhoea and help avoid unplanned pregnancies. They are free at all public clinics.
Let's also remember the link between HIV and tuberculosis (TB). People with HIV are more susceptible to TB. If you have symptoms or have been in contact with someone with TB, get tested. Early detection saves lives.
Health Is Everyone's Business
Building a healthier South Africa is not just about medicine—it is about national prosperity. A healthy population is more productive, more resilient, and more able to seize economic opportunity. Each of us has a role to play in protecting our health and the health of our communities.
Let's work together to end HIV. The finish line is in sight—but only if we don't stop now.
Prof Yogan Pillay is the Director for HIV and TB delivery at the Bill & Melinda Gates Foundation. He was previously the Country Director of the Clinton Health Access Initiative in South Africa and senior director for universal health coverage. He has worked in various capacities at the National Department of Health. In 2021, the University of Cape Town awarded him an honorary doctorate, and in the same year, he was appointed extraordinary professor in the Division of Health Systems and Public Health, Department of Global Health, Stellenbosch University.
Foster Mohale is the National Department of Health Spokesperson
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
TimesLIVE
an hour ago
- TimesLIVE
US-funded contraceptives for poor nations to be burnt in France, sources say
US-funded contraceptives worth nearly $10m (R177.15m) are being sent to France from Belgium to be incinerated after Washington rejected offers from the UN and family planning organisations to buy or ship the supplies to poor nations, two sources told Reuters. A spokesperson for the US state department confirmed to Reuters on Wednesday that a decision had been taken to destroy the stock. The supplies have been stuck for months in a warehouse in Geel, a city in the Belgian province of Antwerp, after President Donald Trump's decision to freeze US foreign aid in January. They comprise contraceptive implants and pills as well as intrauterine devices to help prevent unwanted pregnancies, according to seven sources and a screengrab shared by an eighth source confirming the planned destruction. The US government will spend $167,000 (R2.95m) to incinerate the stocks at a facility in France that handles medical waste, the US state department confirmed. The spokesperson said a preliminary decision had been made to destroy certain products from terminated US Agency for International Development contracts (USAID). 'Only a limited number of commodities have been approved for disposal,' the spokesperson said via email, adding that no condoms or HIV medications would be destroyed. US legislators have introduced two bills this month to prevent the destruction of the supplies after Trump's decision to shut down USAID, but aid groups say the bills are unlikely to be passed in time to stop the incineration.
TimesLIVE
a day ago
- TimesLIVE
Small win for activists, but SA's HIV projects won't get reopened
The $400m that US Congress hasn't cut with the rest of its funding programme doesn't undo the blow to global HIV and TB programmes By The $400m that the US Congress took off a list of programmes from which the Trump administration will now take back previously approved but unspent funds, doesn't mean the cuts to global HIV and TB programmes in February, including those in South Africa, are now reversed. HIV projects that have closed in South Africa, which were formerly funded by the US government, won't restart as a result of this decision. In fact, quite the opposite. The 'limited Pepfar waiver' that President Donald Trump announced in February remains in place. That means no HIV prevention activities, unless they intend to stop pregnant and breastfeeding women from infecting their babies, can be paid for with US government money, and projects that make it easier for teen girls and young women in Africa, trans people, sex workers, injecting drug users and gay and bisexual men — groups of people that have a higher chance to get HIV than the general population — cannot be funded. Without a proper explanation for it, the $400m seems to be a random amount that Trump's administration picked to take back from Pepfar, a US government programme that funds Aids projects in poorer countries with high HIV infection rates, such as South Africa. The amount is about 8.5% of Pepfar's $4.725bn budget for this financial year and was part of a larger $9.4bn 'rescissions package' — that has now been reduced to $9bn and passed as the H.R.4 Rescissions Act of 2025. Rescissions happen when the presidential administration wants to cancel funding that was approved by Congress and then use it for something else. What the decision to remove the $400m from the package does, however, mean is that activism could finally be starting to pay off. Activists have had hundreds of meetings with US senators and Congress committee chairs. There have been 'Save Pepfar' social media campaigns, and plenty of media coverage about the devastating consequences of the funding cuts. Tens of modelling studies have also projected what could happen if the lost funds are not replaced. Opposition from within Trump's Republican Party against nonevidence-based cuts to a programme that has, for two decades, been supported by both the Democrats and Republicans and has saved over 25-million lives, is now at last emerging. 'It's a small win within the bigger context, but nonetheless, a huge win for advocacy, and a reminder that activism is powerful and alive, and making an impact,' Jirair Ratevosian, a former head of staff at Pepfar and fellow at Duke University's Global Health Institute, told Bhekisisa at last week's Conference on HIV Science in Kigali. Around $8bn of the money was for foreign aid and development programmes, including global health, and just over $1bn for public broadcast stations that the Trump administration has accused of being biased because they're too liberal. But the Rescissions Act is, in itself, bad news. 'It opens the floodgates for the Trump administration to say 'we don't want this or that in the budget that Congress approved',' says Mitchell Warren, the head of international advocacy organisation Avac. 'It's trying to take the congressional power of the purse and put it in the executive branch to usurp the role of Congress in deciding how much money — and on what to spend it.' So how did this all happen, and does it hold any good in the long term for South Africa? We break it down. 1. How did we get here? In the US, Congress — it consists of the Senate and the House of Representatives — decides how much government money goes to who, just like parliament does in South Africa. Both the Senate and the House have to pass budgets. But, as analysts at the Centre for Budget and Policy Priorities in Washington, DC point out, President Trump wants more control over how his administration's money is spent. In March, he signed the 2025 budget that Congress approved into law. Three months later, in June, he decided he wanted to change some of that and submitted a $9.4bn rescission request, which the House of Representatives (it has five more Republican than Democrat members) passed on June 12. When it was the Senate's turn to vote on this, some Republican senators weren't happy with the $400m Pepfar cut, signalling they wouldn't sign off on the deal unless the Pepfar part was removed. Because there was a danger of them swinging the vote, the Republicans removed the $400m from the Rescissions Bill and got the House to pass that too. All that's left is for Trump to now sign the Act. 2. What was the $400m that was removed from the Rescissions Act for? In short, no one really knows, because the Trump administration hasn't said what it was for — or what it plans to do with it. But what we do know is that the US law that governs rescissions, the Impoundment Control Act, says that the president can only request that Congress takes back funding that it previously approved, if the money has not yet been obligated — that means funds hadn't yet been given to a particular recipient, for instance, an HIV project in South Africa. We also know that the $400m was part of the financial budget for 2025, says Warren, but because the law gives Pepfar permission to spend money over five years, that money doesn't have to be legally spent until 2029. 3. What will the $400m now be used for? Again, no one knows. We don't even know if it will be used, because over the past few months, the Trump administration's main strategy has 'simply been to illegally impound funds — by announcing a 'funding freeze' or 'programmatic review' with no public notice at all — and force those harmed by the impoundments to pursue relief in court', the Centre on Budget and Policy Priorities explains in an analysis. But we do know what the money can't be used for. Unless the rules of Trump's 'limited waiver' are changed, Pepfar funds can mostly not be spent on any of the evidence-based strategies it paid for before Trump was elected in January. Pepfar used to focus on groups of people and areas where people have the highest chance of getting infected with HIV — that way, the programme got the biggest bang for its buck. In South Africa, for instance, Pepfar worked in the 27 districts with the highest infection rates and groups known as 'key populations' — sex workers, gay and bisexual men, trans people, injecting drug users and African women between the ages of 15 and 24 — that are much more likely to get newly infected with HIV than other South Africans. Now those projects, which studies show stopped many new infections, have been closed down and the Trump administration says it's not prepared to buy HIV prevention medicine for any group other than pregnant and breastfeeding women. 'It used to be all about evidence,' Warren says. 'Now it's all about ideology.' 4. What do scientists and activists want the $400m to be used for? Ratevosian says this moment should be used to gain Republican support to change the waiver rules, so that Pepfar money can cover more of the populations and services needed for HIV prevention. Lenacapavir, a pricey twice-a-year anti-HIV jab, which scientists believe could help to stop HIV in its tracks if it's rolled out properly, could be used to convince Republican Congress members, says Ratevosian. 'Pepfar has long wanted to get countries to transition to taking more ownership [read: pay more] for their HIV responses. So now activists are arguing: 'Preventing more new infections with the jab, will make it easier for countries to take ownership because the pandemic will be easier to manage.'' In December, Pepfar said it would join another organisation, the Global Fund for HIV, TB and Malaria to buy enough lenacapavir for two-million people over three years. But in July, the Global Fund had to go ahead with the deal by itself, because Pepfar seemed to no longer be on board. Warren says: 'If I were in charge, I would take the $400m and double the two million people the Global Fund is planning to cover, because that's how you build a market, prevent new infections more quickly and drive the price down.' 5. What will Pepfar look like in future? Trump's funding cuts didn't kill Pepfar — at least not in theory, but it's a shell of its former self. What it will look like, will depend on the size of its next budget (the Trump administration wants to cut it by 40% but, so far, the House hasn't agreed to that, (the Senate still needs to sit on it) and how much support Republicans who believe in Pepfar can gain to have waiver rules changed. But, Warren points out, 'we're not going to get pre-January projects back; we have to build something different. 'This has been the most seismic shift in democracy. We didn't think we lived in an earthquake zone, but January 20 [when Trump retook office] taught us: you need to be prepared for that earthquake and you therefore need a different infrastructure. 'In an earthquake you don't build back the same thing. You build better, something that is more resilient.' This story was produced by the Bhekisisa Centre for Health Journalism. Sign up for the
IOL News
2 days ago
- IOL News
Why the world must aim to eliminate PEPFAR and end the HIV epidemic
Last week, the President's Emergency Plan for AIDS Relief narrowly escaped a devastating $400 million budget cut thanks to Republican Sens. Susan Collins (Maine) and Lisa Murkowski (Alaska), who voted alongside their Democratic colleagues to protect the program. That was a relief: Since its creation under President George W. Bush in 2003, the anti-HIV/AIDS program has saved an estimated 26 million lives and allowed 7.8 million babies to be born HIV-free. But preserving PEPFAR shouldn't be seen as the end goal. Instead, global health officials should be working toward the day when the world no longer needs it. That ambitious goal might sound far-fetched, given that an estimated 1.3 million people were newly infected with HIV in 2023 globally. But consider this: Last month, the Food and Drug Administration approved a drug called lenacapavir, a twice-yearly injectable treatment that clinical trials have shown is 100 percent effective at preventing HIV infection among young women and 96 percent effective among gay and bisexual men and transgender people. The drug has the potential to be a groundbreaking improvement over the current standard for HIV prevention, oral PrEP (pre-exposure prophylaxis treatment). For all its promise, oral PrEP has confronted the difficult realities of human behaviour. Adhering to a daily medication regimen is challenging under any circumstances, but especially so in communities where HIV-related stigma is pervasive. Even in wealthier countries, gay men who take the medication have been disparaged. Oral PrEP also tends to be less effective in women, though studies differ on whether this is due to lower adherence and access barriers or biological differences in how the medication is absorbed in female anatomy. Lenacapavir, manufactured by Gilead Sciences, could help address these challenges. It is discreet and can be administered privately in a clinical setting. It requires dosing only twice a year, and it is easier and less painful to administer than previous injectable drugs to prevent HIV. In the United States, lenacapavir costs more than $28,000 per person per year before insurance. But Gilead has licensed six generic manufacturers to produce the drug at cost for 120 low- and middle-income countries. Together with the Global Fund, the company has pledged to distribute 2 million doses - still a drop in the bucket compared to what's needed for population-level protection, but a meaningful start. Video Player is loading. Play Video Play Unmute Current Time 0:00 / Duration -:- Loaded : 0% Stream Type LIVE Seek to live, currently behind live LIVE Remaining Time - 0:00 This is a modal window. Beginning of dialog window. Escape will cancel and close the window. Text Color White Black Red Green Blue Yellow Magenta Cyan Transparency Opaque Semi-Transparent Background Color Black White Red Green Blue Yellow Magenta Cyan Transparency Opaque Semi-Transparent Transparent Window Color Black White Red Green Blue Yellow Magenta Cyan Transparency Transparent Semi-Transparent Opaque Font Size 50% 75% 100% 125% 150% 175% 200% 300% 400% Text Edge Style None Raised Depressed Uniform Dropshadow Font Family Proportional Sans-Serif Monospace Sans-Serif Proportional Serif Monospace Serif Casual Script Small Caps Reset restore all settings to the default values Done Close Modal Dialog End of dialog window. Advertisement Next Stay Close ✕ Ad loading Of course, the drug is no silver bullet. Unfortunately none of the licensed generic manufacturers are based in sub-Saharan Africa, the region with the greatest need, and scaling up production could take years. So far, the U.S. is the only country to approve it, and regulatory timelines elsewhere are likely to lag. Nevertheless, lenacapavir is exciting for what it represents: An innovation that can draw PEPFAR into a new era defined not by fighting HIV, but ending it. Advocates of the program should remember that it was designed as an emergency response to an uncontained pandemic; for it to become a permanent fixture of global health would constitute a failure of its mission. Moreover, the program is far from perfect. Like many HIV prevention programs, it often sacrifices preventative care for treatment when budgets tighten. Those trade-offs stand in the way of HIV elimination. The program is also, regrettably, subject to the whims of U.S. politics. In February, Secretary of State Marco Rubio restricted HIV prevention aid so that only pregnant and breastfeeding women can receive it - as if to invite more AIDS epidemics. The world has a long way to go until PEPFAR can safely be shuttered. After all, foundations and private companies cannot replace the program, which provides nearly 70 percent of global financing for HIV/AIDS response. But it's possible to imagine a future in which biomedical science and investments into a sustainable health infrastructure make the program obsolete. That's something the world should strive for. - The Washington Post
